Liposomal Capsule

Capsule-based encapsulation technology constitutes a pharmacologically validated, platform-agnostic solid oral dosage modality for the delivery of liposomally encapsulated vitamins, minerals, nutraceuticals, and other labile bioactive moieties. The system confers superior organoleptic masking, hermetic protection of oxidation- and hydrolysis-sensitive actives, enhanced patient compliance, and granular flexibility in unit-dose titration. For liposome-loaded systems, capsule shell selection across the 000, 00, 0, 1, and 2 size continuum is governed by a rigorous, quality-by-design evaluation of target payload, formulation bulk density, fill-volume capacity, granule morphology, and net encapsulation loading efficiency.

Formulation architecture is engineered to deliver optimal micromeritic behavior including bulk/tapped density, angle of repose, and derived flow indices alongside stringent moisture-activity control and content-uniformity conformance, all while attenuating shear- and thermally-induced perturbation of the phospholipid bilayer architecture during upstream processing. Where indicated, granulation science (wet, dry, or fluid-bed) is deployed to convert the liposomal powder blend into a free-flowing, structurally homogeneous, physically robust particulate matrix compatible with high-throughput, high-precision automated encapsulation platforms. Definitive capsule-format selection is finalized through integrated assessment of fill-weight capacity, bulk volumetric behavior, apparent density, flow-function classification, and dosator/tamping-pin machine compatibility collectively underwriting batch-to-batch reproducibility and consistent in-use product performance.

Key Technical Development Parameters

• Capsule-size rationalization: Empirical selection across the 000–2 shell range, driven by target dose, bulk density, fill-volume kinetics, and formulation payload capacity.
• Micromeritic profiling: Comprehensive characterization of particle-size distribution, bulk/tapped density, Carr’s Compressibility Index, Hausner Ratio, and angle of repose.
• Encapsulation performance validation: Optimization of powder/granule flowability, dosator fill accuracy, fill-weight variation, and content uniformity.
• Liposomal integrity surveillance: Orthogonal monitoring of vesicle particle size, polydispersity index (PDI), zeta potential, encapsulation efficiency (%EE), and residual active potency post-processing.
• Comprehensive product quality release testing: Weight-variation analysis, assay, uniformity of dosage units, Karl Fischer moisture determination, dissolution/release-rate kinetics, and accelerated/long-term stability per.